Tag: Sigma-2 receptor antagonist and serotonin 5-HT2A receptor antagonist with alpha-1A adrenergic receptor antagonism

  • Roluperidone

    Sigma-2 receptor antagonist and serotonin 5-HT2A receptor antagonist with alpha-1A adrenergic receptor antagonism

    A cyclic amide derivative with equipotent nanomolar antagonism at sigma-2 and 5-HT2A receptors, developed by Minerva Neurosciences as monotherapy for the negative symptoms of schizophrenia and distinguished from conventional antipsychotics by the absence of dopaminergic receptor binding.

    Abstract

    Roluperidone (MIN-101, formerly MT-210 and CYR-101) is a cyclic amide (isoindolinone) derivative that combines high-affinity antagonism at the sigma-2 receptor (TMEM97; Ki 8.19 nM) and the serotonin 5-HT2A receptor (Ki 7.53 nM) with lower-affinity antagonism at alpha-1A adrenergic receptors (Ki 4.17 nM), while exhibiting essentially no binding at dopamine D1 through D5 receptors, muscarinic, cholinergic, or histaminergic receptors. This receptor binding profile distinguishes roluperidone from all marketed antipsychotics and underwrites a pharmacological rationale for addressing the negative symptoms of schizophrenia through nondopaminergic mechanisms. The sigma-2 receptor, identified in 2017 as the transmembrane protein TMEM97, is expressed at high density in cortical and hippocampal neurons and is implicated in calcium signaling, cholesterol homeostasis, autophagy, and the modulation of dopaminergic and glutamatergic neurotransmission. The 5-HT2A antagonist component promotes slow-wave sleep normalization, a deficit that is consistently documented in schizophrenia and that correlates with negative symptom severity. Roluperidone was originally synthesized by Mitsubishi Tanabe Pharma Corporation (designated MT-210), licensed through Cyrenaic Pharmaceuticals (CYR-101), and advanced through clinical development by Minerva Neurosciences (MIN-101). In a Phase 2b randomized, double-blind, placebo-controlled trial of 244 patients with stable schizophrenia and moderate-to-severe negative symptoms (MIN-101C03), roluperidone monotherapy at 32 mg/day and 64 mg/day produced statistically significant improvement on the PANSS negative symptom factor score at 12 weeks (effect sizes 0.45 and 0.58, respectively; both p < 0.025). Network intervention analysis of both trials identified avolition as the directly targeted symptom, with improvements cascading across the broader negative symptom constellation. CYP2D6 is involved in metabolism, and poor or intermediate CYP2D6 metabolizers were excluded from the Phase 3 trial. Minerva Neurosciences filed a New Drug Application with the U.S. Food and Drug Administration in April 2023. The FDA issued a Complete Response Letter in February 2024, citing insufficient evidence of effectiveness from a single adequate trial, absence of data on concomitant antipsychotic administration, and the need for additional evidence of clinical meaningfulness. The compound remains in development as of the monograph date. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.